OKYO Pharma (OKYO) Share Price, News & Analysis

Company Overview

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 364,142 shs
• Average Volume: 431,999 shs
• Market Capitalization: £23.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: LON:OKYO
• CIK: N/A
• Web: www.okyopharma.com
• Phone: 44 20 7495 2379
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): GBX (0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -£6.70 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -397.13%
• Return on Assets: -154.72%

Debt

• Debt-to-Equity Ratio: 1.65
• Current Ratio: 0.83
• Quick Ratio: 2.65

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: 28.00
• Book Value: GBX (1) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 1,660,000,000
• Free Float: N/A
• Market Cap: £23.24 million
• Optionable: Not Optionable
• Beta: -0.06